H.C. Wainwright维持GH Research目标价40美元不变
此外，H.C. Wainwright分析师期待GH001在治疗难治性抑郁症方面的关键Phase 3项目可能于2026年上半年启动。他们强调了该药物在治疗TRD方面已显示出的疗效和持久性。分析师还指出，GH Research正在探索GH001的其他适应症，包括产后抑郁症（PPD）和双相II型障碍（BP-II），这可能扩大该药物的市场机会。
来自MSN1 个月
H.C. Wainwright maintains buy on GH Research stock, $40 target
Tuesday, GH Research PLC (NASDAQ:GHRS) received a reiterated Buy rating and $40.00 price target from H.C. Wainwright, representing significant upside potential for the $936 million market cap company.